GlassScriptPhysician profile
Matthew W Schwartz
NPI 1053320424
$169,017.18
in general payments reported to CMS, 2019-2025
50 companies · $48K in 2025
The $48K reported for 2025 was more than what 99% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,766 · 2020: $5,270 · 2021: $16K · 2022: $17K · 2023: $21K · 2024: $53K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $97K · Consulting Fee: $12K · Food and Beverage: $8,233 · Travel and Lodging: $5,119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,580.77 |
| Consulting Fee | $11,571.00 |
| Food and Beverage | $8,232.61 |
| Travel and Lodging | $5,119.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $143,345.28 | 2019-2025 | Libtayo, Lynozyfic |
| Genzyme Corporation | $11,031.17 | 2019-2025 | |
| Regeneron Pharmaceuticals, INC. | $7,826.74 | 2019-2025 | Libtayo |
| Daiichi Sankyo INC. | $1,194.92 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $983.90 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $837.00 | 2022-2025 | Imfinzi, Enhertu, Calquence |
| Novartis Pharmaceuticals Corporation | $523.31 | 2022-2025 | |
| Exelixis INC. | $313.71 | 2021-2025 | Cabometyx |
| Janssen Biotech, INC. | $221.53 | 2022-2025 | Rybrevant, Darzalex, Talvey |
| Genentech USA, INC. | $220.50 | 2023-2025 | Tecentriq, Columvi, Perjeta |
| Amgen INC. | $180.15 | 2022-2023 | Lumakras, Kyprolis, Nplate |
| Sobi, INC | $175.29 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $160.50 | 2022-2025 | Keytruda |
| Beigene USA, INC. | $155.48 | 2023-2024 | Brukinsa |
| Incyte Corporation | $151.56 | 2022-2025 | Jakafi |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $138.94 | 2022-2024 | Reblozyl, Pomalyst |
| Icotec Medical INC. | $123.74 | 2024 | Vader Pedicle System |
| Monteris Medical Corporation | $122.31 | 2024-2025 | Neuroblate |
| Karyopharm Therapeutics INC. | $101.93 | 2023-2025 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $95.82 | 2024 | Fruzaqla, Alunbrig, Vpriv |
| Emd Serono, INC. | $94.35 | 2023-2025 | Bavencio |
| Gilead Sciences, INC. | $86.72 | 2023-2024 | Trodelvy |
| Novocure INC. | $81.58 | 2019-2025 | Optune Lua (Novottf-200t), Optune Gio |
| Astellas Pharma US INC | $58.04 | 2024-2025 | Xospata, Vyloy |
| Stemline Therapeutics INC. | $56.12 | 2023-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $55.13 | 2023-2025 | Orgovyx |
| Eisai INC. | $55.02 | 2023-2025 | |
| Genmab U.S., INC. | $48.20 | 2024-2025 | Tivdak, Epkinly |
| Lilly USA, LLC | $46.53 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Coherus Oncology, INC. | $46.37 | 2025 | Loqtorzi |
| Tempus Ai, INC | $44.74 | 2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $37.93 | 2023-2024 | Krazati |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.59 | 2023 | Gilotrif |
| Seagen INC. | $32.07 | 2023 | Padcev |
| Rigel Pharmaceuticals, INC. | $30.96 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Dendreon Pharmaceuticals LLC | $28.06 | 2024 | Provenge |
| Alnylam Pharmaceuticals INC. | $27.15 | 2025 | Givlaari |
| Azurity Pharmaceuticals, INC. | $25.45 | 2025 | Danziten |
| Avyxa Pharma, LLC | $24.45 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $23.01 | 2023 | Imbruvica |
| Puma Biotechnology, INC. | $21.58 | 2024 | |
| Glaxosmithkline, LLC. | $21.46 | 2023 | Zejula |
| Jazz Pharmaceuticals INC. | $19.75 | 2025 | |
| Inogen, INC. | $18.29 | 2025 | |
| Sirtex Medical INC | $17.77 | 2023 | Sir-Spheres Microspheres |
| Geron Corporation | $17.75 | 2025 | Rytelo |
| Octapharma USA, INC. | $17.05 | 2023 | Octagam Immune Globulin (Human) |
| Pfizer INC. | $16.48 | 2024 | |
| Progenics Pharmaceuticals, INC. | $14.63 | 2024 | |
| Abbvie INC. | $14.17 | 2023 | Lupron Depot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.